» Articles » PMID: 31634549

Evaluation of the BD Phoenix™ CPO Detect Test for the Detection of Carbapenemase Producers

Overview
Publisher Elsevier
Date 2019 Oct 22
PMID 31634549
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Becton-Dickinson recently developed the Phoenix™ CPO (carbapenemase-producing organism) Detect Test, a growth-based test embedded in Gram-negative (GN) panels for the detection and confirmation of bacteria producing class A, B and D carbapenemases. This study aimed to (a) determine the performance of the CPO test, and (b) assess its added value in routine diagnostic workflows.

Methods: The performance of the BD Phoenix CPO test was analysed retrospectively on a collection of 185 molecularly characterized strains, including 92 CPOs, and prospectively on 135 and 160 routine isolates with and without CPO suspicion, respectively.

Results: In the retrospective study the CPO test exhibited 92.4% accuracy (95%CI 87.6-95.8), 97.8% sensitivity (95%CI 92.4-99.7) and 87.1% specificity (95%CI 78.6-93.2) for carbapenemase detection. The CPO test provided a classification to class A, B, and D for 81.3% of detected carbapenemases with 94.6% accuracy (95%CI 86.7-98.5). In the prospective study the CPO test detection performance showed 77.8% accuracy (95%CI 68.8-84.5), 100% sensitivity (95%CI 91.2-100) and 67.8% specificity (95%CI 57.3-77.1) with 135 CPO-suspicious isolates and 98.8% accuracy and specificity (95%CI 95.6-99.9) with 160 non-CPO-suspicious isolates. Compared to routine testing, the implementation of the CPO test allowed a mean reduction of 21.3 h (95%CI 17.6-25) in turnaround time, 16.8 min (95%CI 13.4-20.2) in hands-on time, and 20.6 CHF (95%CI 16.5-24.8) in costs.

Conclusions: The CPO test is reliable for the detection of CPO with a high sensitivity. However, the relatively low detection specificity required the use of additional confirmatory methods. The carbapenemase classification accuracy is robust in providing preliminary results before molecular characterization. Finally, the implementation of the test in routine workflows allowed a significant reduction in turnaround time, hands-on time and cost compared to the conventional approach.

Citing Articles

Performance comparison of BD Phoenix CPO detect panel with Cepheid Xpert Carba-R assay for the detection of carbapenemase-producing Klebsiella pneumoniae isolates.

Tuzemen N, Onal U, Merdan O, Akca B, Ener B, Akalin H BMC Microbiol. 2024; 24(1):168.

PMID: 38760674 PMC: 11100183. DOI: 10.1186/s12866-024-03311-7.


Evaluation of the BD Phoenix Carbapenemase-Producing Organism Panels for the Detection of Carbapenemase Producers in and .

Correa-Leon Y, Perez-Hernandez J, Martinez-Guerra B, Rodriguez-Noriega E, Mena-Ramirez J, Lopez-Gutierrez E Diagnostics (Basel). 2023; 13(22).

PMID: 37998553 PMC: 10670751. DOI: 10.3390/diagnostics13223417.


Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant .

Gill C, Rajkotia P, Roberts A, Tenover F, Nicolau D Emerg Microbes Infect. 2023; 12(1):2179344.

PMID: 36786132 PMC: 9980414. DOI: 10.1080/22221751.2023.2179344.


Performance Evaluation of the Quantamatrix QMAC-dRAST System for Rapid Antibiotic Susceptibility Testing Directly from Blood Cultures.

Rosselin M, ProdHom G, Greub G, Croxatto A Microorganisms. 2022; 10(6).

PMID: 35744730 PMC: 9229829. DOI: 10.3390/microorganisms10061212.


Performance Evaluation of Diagnostic Assays for Detection and Classification of Carbapenemase-Producing Organisms.

Zhang A, Wang X, Liang X, Zhou C, Wang Q, Zhang J Antibiotics (Basel). 2021; 10(12).

PMID: 34943669 PMC: 8698775. DOI: 10.3390/antibiotics10121457.